Drug Trial Radar · NCT00289783
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
Last checked: Nov 20, 2026Latest source record: Aug 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,441
Actual
Start
Feb 22, 2006
Primary completion
Aug 27, 2007
Study completion Feb 26, 2008
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 weeks, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT vaccine lots and the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with Pediarix® to healthy infants at 2, 4, and 6 months of age. The study will also evaluate the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with M-M-R® II and Varivax® at 12 to 15 months of age.
Conditions
- Haemophilus Influenzae Type b
- Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccineBiological
3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
ActHIBBiological
3-dose intramuscular injection at 2, 4 and 6 months of age.
PedvaxHIBBiological
1 booster dose by intramuscular injection at 12 to 15 months of age.
PediarixBiological
3-dose intramuscular injection at 2, 4 and 6 months of age.
PrevnarBiological
3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
M-M-R IIBiological
1 booster dose by subcutaneous injection at 12 to 15 months of age.
VarivaxBiological
1 booster dose by subcutaneous injection at 12 to 15 months of age
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anti-Polyribosyl Ribitol Phosphate (PRP) Antibody ConcentrationsTime frame: One month after primary vaccination
- Neisseria Meningitidis Serogroup C (MenC) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody TitersTime frame: One month after primary vaccination
- Neisseria Meningitidis Serogroup Y (MenY) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody TitersTime frame: One month after primary vaccination
- hSBA-MenC Antibody TitersTime frame: Prior to the fourth dose vaccination and 42 days after the fourth dose
- hSBA-MenY Antibody TitersTime frame: Prior to the fourth dose vaccination and 42 days after the fourth dose
- Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (µg/mL)Time frame: One month after primary vaccination
- Number of Subjects With hSBA-MenC Titer Equal to or Above 1:8Time frame: 42 days after the fourth dose
- Number of Subjects With hSBA-MenY Titer Equal to or Above 1:8Time frame: 42 days after the fourth dose
- Number of Subjects With Anti-measles Antibody Concentrations Equal to or Above 150 Milli-international Units Per Milli-liter (mIU/ML)Time frame: 42 days after the fourth dose
- Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per MilliliterTime frame: 42 days after the fourth dose
- Number of Subjects With Anti-mumps Titer Equal to or Above 28 Estimated Dose 50 (ED50)Time frame: 42 days after the fourth dose
- Number of Subjects With Anti-rubella Antibody Concentrations Equal to or Above 10 International Units Per Milli-litre (IU/mL)Time frame: 42 days after the fourth dose
- Number of Subjects With Anti-varicella Titer Equal to or Above 1:5Time frame: 42 days after the fourth dose
Locations
93 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Bryant, Arkansas
GSK Investigational Site
Fayetteville, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
East Artesia, California
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Paramount, California
GSK Investigational Site
Rolling Hills Estates, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
West Covina, California
GSK Investigational Site
Longmont, Colorado
GSK Investigational Site
Norwich, Connecticut
GSK Investigational Site
Cocoa Beach, Florida
GSK Investigational Site
Melbourne, Florida
GSK Investigational Site
Pembroke Pines, Florida
GSK Investigational Site
Rockledge, Florida
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Des Moines, Iowa
GSK Investigational Site
Des Moines, Iowa
GSK Investigational Site
Arkansas City, Kansas
GSK Investigational Site
Kansas City, Kansas
GSK Investigational Site
Bardstown, Kentucky
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Bossier City, Louisiana
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Fall River, Massachusetts
GSK Investigational Site
Jamaica Plain, Massachusetts
GSK Investigational Site
Kalamazoo, Michigan
GSK Investigational Site
Portage, Michigan
GSK Investigational Site
Stevensville, Michigan
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.